Back to top
more

Alimera Sciences (ALIM)

(Delayed Data from NSDQ)

$5.56 USD

5.56
125,411

-0.04 (-0.71%)

Updated Jul 15, 2024 04:00 PM ET

After-Market: $5.56 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (83 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Spero's (SPRO) IND Accepted by FDA for Pulmonary Disease Drug

The FDA accepts Spero's (SPRO) IND for SPR720 in development for the treatment of nontuberculous mycobacterial pulmonary disease.

Reasons to Invest in Dr. Reddy's (RDY) Amid Coronavirus Woes

Dr. Reddy's (RDY) continues to make products launches despite tepid sales volumes due to the COVID-19 pandemic.

Alnylam's Share Price Rises YTD on Pipeline Developments

Alnylam's (ALNY) share price rises more than 14% year to date based on pipeline developments.

Bristol Myers' Idhifa Fails to Meet Goal in Leukemia Study

Bristol Myers' (BMY) phase III study evaluating Idhifa in patients with relapsed or refractory acute myeloid leukemia fails to meet the primary endpoint.

5 Reasons to Invest in Horizon Therapeutics Amid Coronavirus

Horizon Therapeutics (HZNP) expects continued strong growth for Krystexxa and Tepezza, going forward in 2020. The company's efforts to develop its pipeline are impressive.

Pluristem Completes Enrollment in Phase I Hematology Study

Pluristem (PSTI) completes enrollment in the phase I study in patients with complete hematopoietic recovery following hematopoietic cell transplantation in the United States and Israel.

Unity Shares Slump 66% As Lead Arthritis Drug Fails in Study

Unity's (UBX) lead pipeline candidate, UBX0101, fails to meet primary endpoint in a phase II study in patients with moderate-to-severe painful osteoarthritis of the knee.

Novo Nordisk (NVO) Resumes Phase III Hemophilia Studies

Novo Nordisk (NVO) resumes the phase III studies on concizumabin in hemophilia A and B patients regardless of inhibitor status.

AVEO Pharmaceuticals' (AVEO) Q2 Earnings Surpass Estimates

AVEO (AVEO) reports a narrower-than-expected loss but misses sales estimates in the second quarter of 2020.

Amicus' (FOLD) Q2 Earnings Surpass Estimates, Revenues Miss

Amicus (FOLD) posts a narrower-than-expected loss, while sales beat estimates in the second quarter of 2020.

Aerie (AERI) Q2 Earnings Miss Estimates, Revenues Rise Y/Y

Aerie (AERI) posts a wider-than-expected loss and sales miss estimates in the second quarter of 2020.

AMAG Pharmaceuticals' (AMAG) Q2 Loss Narrower Than Expected

AMAG (AMAG) posts a narrower-than-expected loss and revenues miss estimates in the second quarter of 2020.

ACADIA (ACAD) Q2 Earnings Surpass, Nuplazid Drives Sales

ACADIA (ACAD) beats on earnings and revenues for the second quarter. The company lifts the lower end of its net sales view for Nuplazid, driving the stock in pre-market trading.

Horizon (HZNP) Q2 Earnings Down Y/Y, Tepezza Drives Sales

Horizon Therapeutics' (HZNP) earnings decline year over year and sales beat estimates in the second quarter of 2020.

Zoetis' (ZTS) Q2 Earnings and Revenues Surpass Estimates

Zoetis (ZTS) beats both earnings and sales estimates in the second quarter of 2020.

What Makes Alimera Sciences (ALIM) a New Strong Buy Stock

Alimera Sciences (ALIM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Tirthankar Chakraborty headshot

New Strong Buy Stocks For August 5th

Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today:

Alimera Sciences (ALIM) Reports Q2 Loss, Tops Revenue Estimates

Alimera Sciences (ALIM) delivered earnings and revenue surprises of 76.17% and 336.44%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Alimera (ALIM) to Report Q2 Earnings: What's in the Cards?

Alimera (ALIM) will provide updates on its corporate developments during the second-quarter 2020 earnings release.

Tirthankar Chakraborty headshot

New Strong Buy Stocks For June 25th

Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today:

EyePoint Pharmaceuticals (EYPT) Surges: Stock Moves 7.4% Higher

EyePoint Pharmaceuticals (EYPT) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

Tirthankar Chakraborty headshot

New Strong Buy Stocks for June 16th

Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today.

Alimera Sciences (ALIM) Reports Q1 Loss, Tops Revenue Estimates

Alimera Sciences (ALIM) delivered earnings and revenue surprises of 44.19% and 3.53%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Alimera Sciences (ALIM) Tops Q4 Earnings and Revenue Estimates

Alimera Sciences (ALIM) delivered earnings and revenue surprises of 121.62% and 19.64%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Alimera Sciences Sees Hammer Chart Pattern: Time to Buy?

Alimera Sciences has been struggling lately, but the selling pressure may be coming to an end soon.